demonstrated sensitivity and specificity for bacterial infection [5] -would be elevated in acute CDI, but not in a UC flare or C. difficile colonization, enabling more rapid and accurate treatment decisions.
In patients with diarrhea and recent antibiotic exposure, and without other intestinal pathologies, the clinical dilemma while awaiting a C. difficile test result is primarily whether one should empirically start antibiotics to cover CDI. In UC, however, there is an added layer of complexity. The symptoms of CDI largely overlap with those of an acute UC flare, for which the treatment of choice would be immunosuppression. Standard UC flare treatment would begin with corticosteroids, progressing to anti-TNF medications or calcineurin inhibitors in the right clinical setting [2] . Treatments that increase immunosuppression are relatively contraindicated in the setting of untreated CDI [6] . Waiting to start immunosuppression in a severe UC flare can increase the morbidity of the disease, and the time it can take to exclude CDI as a cause of intensifying symptoms may be an explanation for the worsened long-term outcomes in UC patients who experience CDI [7] .
Furthermore, although the C. difficile PCR assay has excellent performance characteristics, the laboratory test alone cannot differentiate between infection and asymptomatic colonization [8] . This becomes even more problematic in UC, where a higher prevalence of colonization with C. difficile exists and the symptoms of UC flare and CDI have considerable overlap [9] [10] [11] . Therefore, a reliable surrogate marker for CDI has clear value in the UC population.
The aim of our trial was to study the role PCT may play as such a marker. We sought to compare the PCT levels of UC patients with new-onset or worsening diarrhea, hypothesizing that PCT, but not traditional biomarkers such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), or white blood cell (WBC) count, would discriminate between C. difficile positive and negative groups. Furthermore, we hypothesized that among UC patients with a positive C. difficile assay, higher PCT levels would discriminate between those who would and would not improve with antibiotic treatment, implying that their presentation was caused by a UC flare with asymptomatic C. difficile colonization.
Methods

Sample Testing and Clinical Epidemiology
The University of Michigan institutional review board approved this study. Our design was a single center, prospective cohort study. From July 2013 to August 2016, we obtained notifications from the University of Michigan clinical laboratory of any adult, inpatient or outpatient, with a previous diagnosis of UC (by International Classification of Diseases, Ninth Revision code) who submitted a stool sample for C. difficile testing. After manually verifying the UC diagnosis through chart review, we included all patients who had a serum sample suitable for PCT testing collected concurrently with stool samples. We excluded patients who were status-post a total colectomy or who were diagnosed with another infection, as this could also increase PCT and decrease the specificity of our analysis. Serum PCT measurement was performed with a polystyrene, antibody-coated, bead-based assay ( The data warehouse query included the age of patient at testing, date of C. difficile sample, and date of serum sample, to which our study coordinator added the results of C. difficile and PCT testing. Our investigators (A.R.R., J.L., E.B., B.R., and T.F.) then performed manual review in the university's electronic medical record systems to obtain information on sex, verification of UC diagnosis and phenotype, concomitant steroids, immunomodulators, antitumor necrosis factor agents, history of CDI, recent exposure to antibiotics, ESR, CRP, WBC count, admission hemoglobin, and minimum serum albumin. We followed the clinical course to see whether any non-CDI infections were diagnosed, and whether treatment for a UC flare was initiated.
Statistical Analysis
After performing data cleaning and calculating descriptive statistics including measures of central tendency and spread, the data with symmetrical distributions were presented as mean and SD; the data with skewedness were presented as median, range, and interquartile range (IQR). Categorical data were presented as percentages. To compare between the CDI and no-CDI groups, unpaired t tests were used for the symmetrically distributed continuous data, and either log transformation followed by a t test (if transformation restored a normal distribution) or Wilcoxon rank sum test was used for the data with asymmetrical distribution. The chisquare test was used to compare the categorical data. A second, pre-planned analysis sub-classified the CDI-positive patients by whether they responded to anti-C. difficile antibiotics (CDI-R) versus whether they did not respond (CDI-NR). In all cases, the nonresponders were treated with initiation or intensification of immunosuppression, making their response to antibiotics a proxy for whether their symptoms were due to a "true" CDI versus a UC flare with a "false-positive" C. difficile assay. We then examined biomarker differences between the 2 groups. A 2-sided p value of <0.05 was considered statistically significant for all analyses.
Logistic regression analysis was performed to find a combination of parameters that could differentiate between UC with CDI versus UC without CDI, as well as between CDI-R versus CDI-NR. The parameters with significant correlations with other parame-ters (Pearson correlation coefficient, r ≥ 0.5) were identified by construction of a correlation matrix, and were selectively excluded from analyses. The predictive models including the non-correlated, significant parameters based on logistic regression results were built. The backward selection method was used to select predictors in the final multivariate model. The areas under the receiver operating characteristic curve of each model were reported. Data analysis was performed with STATA 12 (StataCorp, College Station, TX, USA), R version 3.0.2 (R Foundation for Statistical Computing, Vienna, Austria), and SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
A total of 137 patients were enrolled: 65 outpatients and 72 inpatients. Of the 20 excluded patients, 18 were diagnosed with infections other than CDI that had not been detected on initial enrollment, 1 had a different direct PCR test for C. difficile and was negative for GDH/ toxin on our standard multistep testing protocol, and 1 was completely asymptomatic. Of the remaining 117 patients, 62 were outpatients and 55 were inpatients. In the 27 patients with CDI, 11 were inpatients. Descriptive characteristics of the study cohort stratified by CDI status, including age, sex, inpatient status, concomitant UC medications, prior CDI, and recent antibiotic use are presented in Table 1 , and differed only in the likelihood of having had a prior CDI -59% of those who were eventually diagnosed with CDI had a previous CDI, while only 14% of the C. difficile -negative group had a prior CDI ( p < 0.01).
Procalcitonin
Serum PCT was measured in all 117 patients. In the 27 patients with CDI, the median was 60.7 pg/mL (range 26.0-560.6, IQR 31.7-116.3). In the 90 patients without CDI, the median PCT was 56.7 pg/mL (25.1-2,252, IQR 40.3-82.5; Fig. 1 ; Table 2 ). The levels were not statistically different between the 2 groups ( p = 0.79). The area under the receiver operator characteristic curve (AUC) for this comparison was 0.51 (95% CI 0.42-0.60).
Other Inflammatory Markers
We also looked at differences in CRP and serum WBC count between the groups with and without CDI. For CRP, the median was 0. 
Inflammatory Markers and Response to Antibiotic Treatment
While PCT did not discriminate between those with and without a positive stool test for C. difficile , it did differentiate those patients who would or would not respond to antibiotic therapy alone. Of the 27 patients with UC and a positive C. difficile assay, 5 were treated concurrently for a UC flare and CDI. The remaining 22 were started solely on antibiotics to cover C. difficile -that is, the treating physicians' initial impressions were that the presentation of these patients was solely due to CDI. Of these, 19 patients were treated with standard-dose oral vancomycin, while 3 of them received metronidazole. Of these 22 patients, 14 responded (CDI-R) completely to treatment, and needed no changes in therapy for their UC, while 8 did not respond (CDI-NR) to treatment, and were subsequently treated for a UC flare with symptom improvement. The median PCT for the CDI-R group was 105. ( Fig. 1 ) . The area under the receiver operator characteristic curve (AUC) for this comparison was 0.71 (95% CI 0.5-0.93; Fig. 2 a) . Neither initial antibiotic choice (vancomycin vs. metronidazole) nor mode of laboratory diagnosis (positive GDH and toxin EIA vs. positive GDH EIA, negative toxin EIA, positive toxin PCR) differentiated CDI-R from CDI-NR (chi-square NS for both).
Multivariable Logistic Regression
For the distinction between the CDI and no-CDI groups, no covariates met our threshold to be included in a multivariate model. For the CDI-R versus CDI-NR distinction, our model combined PCT with WBC and HGB, obtaining an AUC of 0.86 (95% CI 0.7-1; Fig. 2 b) .
Discussion
Despite recent advances in laboratory diagnosis of C. difficile , differentiating CDI from a UC flare remains the rate-limiting step in the evaluation and treatment of patients with UC who present with diarrhea, abdominal pain, and other symptoms compatible with both conditions. In this setting, an inexpensive, rapid, point-of-care test that could serve as a surrogate marker would have Comparison of log-transformed procalcitonin levels among groups. We did not find a significant difference between the UC patients that did and did not have a positive Clostridium difficile assay ( p = 0.79), but we did find a difference between CDI-R and CDI-NR groups ( p = 0.036). CDI-R, Clostridium difficile infection (in ulcerative colitis) with response to antibiotic therapy; CDI-NR, Clostridium difficile infection (in ulcerative colitis) without response to antibiotic therapy; UC, ulcerative colitis with negative Clostridium difficile testing.
clear value, aiding clinicians in rapid treatment decisions. Current widely used surrogate markers, however, have performance characteristics that prevent them from being useful in this scenario. ESR and CRP are commonly used markers of systemic inflammation. These are both consistently elevated in infectious gastroenteritis, including CDI, as well as in systemic autoinflammatory conditions such as UC, and are unable to discriminate between the 2 conditions [12] . Markers of luminal intestinal inflammation likewise lack specificity. Fecal leukocytes and fecal occult blood can be found in both UC and CDI. Fecal lactoferrin and calprotectin are likewise nonspecific, with the added issues of higher cost and longer turnaround time than the C. difficile assay itself.
In other situations where quickly differentiating a bacterial infection from a similarly presenting viral or noninfectious process is critical, PCT has shown usefulness, and is gaining wider acceptance. For example, in patients presenting to the emergency department with dyspnea, PCT has great value in discriminating bacterial pneumonia from congestive heart failure [13] . Similarly, in critical care medicine, algorithms utilizing PCT to differentiate infectious from noninfectious illnesses and to guide antibiotic therapy in sepsis have proven to improve treatment decisions and reduce antibiotic overuse [5] . Previous studies have found PCT to maintain a high sensitivity for infectious complications despite the presence of concomitant autoimmune disease, though this has not been widely studied [14, 15] .
Our study set out to investigate whether PCT could differentiate an active C. difficile infection from a flare of UC. To fill this role, however, PCT would need to be reliably elevated in CDI, and not in UC. In our study, we only saw this difference when comparing CDI treatment responders to CDI treatment non-responders, rather than with all CDI+ to CDI-patients. This may reflect the diagnostic uncertainty inherent in C. difficile testing, where positive PCR tests cannot distinguish colonization from true infection, but response to CDI therapy acts as a reasonable surrogate marker for "true CDI." As expected, none of the traditional biomarkers of inflammation alone did any better at discriminating CDI from UC flares, as ESR, CRP, and WBC count were similarly elevated in both populations.
The other question of note is why PCT was elevated in so many of the UC patients who were negative for CDI. In early literature, PCT was reported to be elevated in selflimited colitis, but not in UC [16] . However, in a subsequent study assessing PCT as a potential disease activity marker in IBD, PCT was found to be both elevated and proportional to severity in both Crohn's and UC [17, 18] . Most recently, a study showed that PCT levels in patients with severe UC were significantly higher than those in patients with mild or moderate UC, who themselves were indistinguishable by PCT from healthy controls [19] .
Compared to other autoimmune disorders that have been shown to not elevate PCT, how is UC, particularly severe UC, different? We can only speculate, but a likely mechanism relates to the dysfunction of the colonic mucosal barrier in an ulcerated, inflamed colon. This barrier dysfunction exposes more bacterial antigens to the systemic circulation, which, while not an infection, could well trigger the inflammatory cascade of which PCT is a byproduct.
In the mixed population described in this study, it does not appear that PCT is suitable for our intended goal, discriminating an acute UC flare from all cases of CDI. It may, however, associate with CDI patients who ultimately respond to antimicrobials and, thus, have "true CDI" as opposed to colonization. Further study is warranted as to how PCT can best be incorporated into IBD treatment algorithms, and for describing more fully the endoscopic and pathophysiologic correlates of elevated PCT levels.
